Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama
Open Access
- 23 July 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (8) , 899
Abstract
Escherichia coli represents one of the most common causes of community-onset and nosocomial infections. Strains carrying extended spectrum β-lactamases (ESBL) are a serious public health problem. In Central America we have not found studies reporting the molecular epidemiology of E. coli strains implicated in local infections, so we conducted this study to fill that gap. Materials and Methods: We report on an epidemiological study in two reference hospitals from central Panama, identifying the susceptibility profile, associated risk factors, and molecular typing of E. coli strains isolated between November 2018 and November 2019 using Pasteur’s Multilocus Sequence Typing (MLST) scheme. Results: A total of 30 E. coli isolates with antimicrobial resistance were analyzed, 70% of which came from inpatients and 30% from outpatients (p < 0.001). Two-thirds of the samples came from urine cultures. Forty-three percent of the strains were ESBL producers and 77% were resistant to ciprofloxacin. We identified 10 different sequence types (STs) with 30% of the ESBL strains identified as ST43, which corresponds to ST131 of the Achtman MLST scheme—the E. coli pandemic clone. Thirty-eight percent of the E. coli strains with the ESBL phenotype carried CTX-M-15. Conclusions: To the best of our knowledge, this is the first report confirming the presence of the pandemic E. coli clone ST43/ST131 harboring CTX-M-15 in Central American inpatients and outpatients. This E. coli strain is an important antimicrobial-resistant organism of public health concern, with potential challenges to treat infections in Panama and, perhaps, the rest of Central America.Keywords
This publication has 36 references indexed in Scilit:
- Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment OptionsDrugs, 2019
- Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniaeInfection, Genetics and Evolution, 2018
- Evolutionary History of the Global Emergence of the Escherichia coli Epidemic Clone ST131mBio, 2016
- Guide to the various phylogenetic classification schemes for Escherichia coli and the correspondence among schemesMicrobiology, 2015
- Rapid and Specific Detection, Molecular Epidemiology, and Experimental Virulence of the O16 Subgroup within Escherichia coli Sequence Type 131Journal of Clinical Microbiology, 2014
- Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic ResistanceFrontiers in Microbiology, 2012
- Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case–control study in a French teaching hospitalClinical Microbiology and Infection, 2011
- Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-Lactamase-producing Klebsiella pneumoniaeAmerican Journal of Infection Control, 2011
- Infections with Extended-Spectrum β-Lactamase-Producing EnterobacteriaceaeDrugs, 2010
- Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamasesJournal of Antimicrobial Chemotherapy, 2006